Replies to post #83831 on Biotech Values

[ThomasS]

MNTA: I read the entire report. The thesis laid out to erode confidence in a MNTA-only generic Lovenox FDA approval had the opposite effect on me. In fact, I'd suggest that the author made the case in favor of Momenta.
One would be left with the impression that a competitor of Momenta may have ghost-written the thing!